Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 919

1.

Combining Dual Bronchodilation and β-Blockade in Patients With an Overlap Between COPD and Cardiovascular Diseases.

Cazzola M, Matera MG.

Chest. 2018 Jun;153(6):1289-1291. doi: 10.1016/j.chest.2018.01.032. No abstract available.

PMID:
29884246
2.

Zeta Potential Measurements on Solid Surfaces for in Vitro Biomaterials Testing: Surface Charge, Reactivity Upon Contact With Fluids and Protein Absorption.

Ferraris S, Cazzola M, Peretti V, Stella B, Spriano S.

Front Bioeng Biotechnol. 2018 May 9;6:60. doi: 10.3389/fbioe.2018.00060. eCollection 2018.

3.

Editorial overview: Respiratory: Pulmonary pharmacology - It is time for a breath of fresh air.

Cazzola M, Matera MG.

Curr Opin Pharmacol. 2018 May 30. pii: S1471-4892(18)30047-X. doi: 10.1016/j.coph.2018.05.011. [Epub ahead of print] No abstract available.

PMID:
29859765
4.

Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells.

Matera MG, Calzetta L, Gritti G, Gallo L, Perfetto B, Donnarumma G, Cazzola M, Rogliani P, Donniacuo M, Rinaldi B.

Eur J Pharmacol. 2018 Aug 5;832:114-119. doi: 10.1016/j.ejphar.2018.05.023. Epub 2018 May 18.

PMID:
29782855
5.

Chronic Obstructive Pulmonary Disease and Stroke.

Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Cazzola M, Siafakas N.

COPD. 2018 May 10:1-9. doi: 10.1080/15412555.2018.1464551. [Epub ahead of print]

PMID:
29746193
6.

Efficacy and safety profile of xanthines in COPD: a network meta-analysis.

Cazzola M, Calzetta L, Barnes PJ, Criner GJ, Martinez FJ, Papi A, Gabriella Matera M.

Eur Respir Rev. 2018 May 2;27(148). pii: 180010. doi: 10.1183/16000617.0010-2018. Print 2018 Jun 30. Review.

7.

The safety of dual bronchodilation on cardiovascular serious adverse events in COPD.

Rogliani P, Ora J, Matera MG, Cazzola M, Calzetta L.

Expert Opin Drug Saf. 2018 Jun;17(6):589-596. doi: 10.1080/14740338.2018.1472232. Epub 2018 May 14.

PMID:
29716427
8.

Indacaterol/Glycopyrronium in Clinical Practice: The Italian Experience.

Cazzola M.

Respiration. 2018;95 Suppl 1:1-2. doi: 10.1159/000486881. Epub 2018 Apr 27. No abstract available.

9.

Impact of doxofylline in COPD: A pair-wise meta-analysis.

Cazzola M, Calzetta L, Rogliani P, Page C, Matera MG.

Pulm Pharmacol Ther. 2018 Apr 26. pii: S1094-5539(18)30094-4. doi: 10.1016/j.pupt.2018.04.010. [Epub ahead of print]

10.

Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.

Calzetta L, Matera MG, Facciolo F, Cazzola M, Rogliani P.

Respir Res. 2018 Apr 12;19(1):65. doi: 10.1186/s12931-018-0770-7.

11.

N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.

Calzetta L, Rogliani P, Facciolo F, Rinaldi B, Cazzola M, Matera MG.

Biomed Pharmacother. 2018 Jul;103:1-8. doi: 10.1016/j.biopha.2018.04.011. Epub 2018 Apr 24.

12.

Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy.

Calzetta L, Matera MG, Cazzola M.

Curr Opin Pharmacol. 2018 Apr 4;40:95-103. doi: 10.1016/j.coph.2018.03.011. [Epub ahead of print] Review.

PMID:
29626716
13.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.

Haematologica. 2018 Apr 5. pii: haematol.2017.185751. doi: 10.3324/haematol.2017.185751. [Epub ahead of print] No abstract available.

14.

Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis.

Rogliani P, Matera MG, Puxeddu E, Mantero M, Blasi F, Cazzola M, Calzetta L.

Pulm Pharmacol Ther. 2018 Jun;50:28-37. doi: 10.1016/j.pupt.2018.03.004. Epub 2018 Mar 30.

PMID:
29609004
15.

Is ICS-LAMA an alternative option to treat patients with COPD?

Rogliani P, Calzetta L, Cazzola M.

Lancet Respir Med. 2018 May;6(5):316-317. doi: 10.1016/S2213-2600(18)30139-5. Epub 2018 Apr 5. No abstract available.

PMID:
29605621
16.

MYD88 mutated and wild-type Waldenströms Macroglobulinemia: Characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4.

Guerrera ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, Chan GG, Manning RJ, Liu X, Chen JG, Munshi M, Patterson CJ, Castillo JJ, Dubeau T, Gustine J, Carrasco RD, Arcaini L, Varettoni M, Cazzola M, Treon SP, Hunter ZR.

Haematologica. 2018 Mar 29. pii: haematol.2018.190181. doi: 10.3324/haematol.2018.190181. [Epub ahead of print] No abstract available.

17.

Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting.

Ferrara R, Ientile V, Piccinni C, Pasqua A, Pecchioli S, Fontana A, Alecci U, Scoglio R, Magliozzo F, Torrisi SE, Vancheri C, Vitulo P, Fantaci G, Ferrajolo C, Cazzola M, Cricelli C, Caputi AP, Trifirò G.

NPJ Prim Care Respir Med. 2018 Mar 23;28(1):10. doi: 10.1038/s41533-018-0077-7.

18.

Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD.

Donner CF, Amaducci S, Bacci E, Baldacci S, Bartoli ML, Beghi GM, Benfante A, Brighindi S, Casali L, Castiglia D, Cazzola M, Celi A, Cianchetti S, Colombo G, Crimi C, Dente FL, Di Maria G, Di Maria A, Latorre M, Lavorini F, Maio S, Mannini C, Messina R, Paggiaro PL, Pignatti P, Price D, Scichilone N, Simoni M, Spanevello A, Stagno d'Alcontres M, Tan S, Torchio R, Viegi G, Visca D, Wouters EFM, Yu Hui Xin S.

Monaldi Arch Chest Dis. 2018 Feb 2;88(1):886. doi: 10.4081/monaldi.2018.886.

19.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.

De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Censori B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9.

20.

How does race/ethnicity influence pharmacological response to asthma therapies?

Cazzola M, Calzetta L, Matera MG, Hanania NA, Rogliani P.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):435-446. doi: 10.1080/17425255.2018.1449833. Epub 2018 Mar 12. Review.

PMID:
29528249
21.

Benralizumab for the treatment of asthma.

Matera MG, Rogliani P, Calzetta L, Canonica GW, Cazzola M.

Drugs Today (Barc). 2017 Dec;53(12):633-645. doi: 10.1358/dot.2017.53.12.2736670. Review.

PMID:
29517082
22.

A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD.

Matera MG, Calzetta L, Puxeddu E, Rogliani P, Cazzola M.

Expert Opin Drug Saf. 2018 May;17(5):509-517. doi: 10.1080/14740338.2018.1448786. Epub 2018 Mar 8.

PMID:
29505318
23.

Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.

Cazzola M, Matera MG, Levi-Schaffer F, Rogliani P.

Expert Opin Drug Saf. 2018 Apr;17(4):429-435. doi: 10.1080/14740338.2018.1446940. Epub 2018 Mar 8. Review.

PMID:
29486600
24.

Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how.

Calzetta L, Matera MG, Rogliani P, Cazzola M.

Expert Rev Respir Med. 2018 Apr;12(4):261-264. doi: 10.1080/17476348.2018.1442216. Epub 2018 Feb 19. No abstract available.

PMID:
29451042
25.

Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved.

Cazzola M, Rogliani P, Matera MG.

Pol Arch Intern Med. 2018 Jan 31;128(1):4-6. doi: 10.20452/pamw.4197. Epub 2018 Jan 31. No abstract available.

26.

Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study.

Rogliani P, Ora J, Puxeddu E, Calzetta L, Cavalli F, Matera MG, Cazzola M.

Pulm Pharmacol Ther. 2018 Apr;49:20-26. doi: 10.1016/j.pupt.2017.12.010. Epub 2017 Dec 30.

PMID:
29294360
27.

Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.

Matera MG, Rogliani P, Calzetta L, Cazzola M.

Expert Opin Drug Metab Toxicol. 2018 Feb;14(2):239-245. doi: 10.1080/17425255.2018.1421170. Epub 2017 Dec 27. Review.

PMID:
29268638
28.

Doxofylline is not just another theophylline!

Matera MG, Page C, Cazzola M.

Int J Chron Obstruct Pulmon Dis. 2017 Dec 5;12:3487-3493. doi: 10.2147/COPD.S150887. eCollection 2017. Review.

29.

The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis.

Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L.

Int J Chron Obstruct Pulmon Dis. 2017 Dec 5;12:3469-3485. doi: 10.2147/COPD.S146338. eCollection 2017.

30.

Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.

Rumi E, Boveri E, Bellini M, Pietra D, Ferretti VV, Sant'Antonio E, Cavalloni C, Casetti IC, Roncoroni E, Ciboddo M, Benvenuti P, Landini B, Fugazza E, Troletti D, Astori C, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Oncotarget. 2017 Oct 6;8(60):101735-101744. doi: 10.18632/oncotarget.21594. eCollection 2017 Nov 24.

31.

Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.

Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG.

Pulm Pharmacol Ther. 2018 Feb;48:185-194. doi: 10.1016/j.pupt.2017.11.009. Epub 2017 Dec 9.

PMID:
29233650
32.

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A.

J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.

PMID:
29226763
33.

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.

Zini R, Guglielmelli P, Pietra D, Rumi E, Rossi C, Rontauroli S, Genovese E, Fanelli T, Calabresi L, Bianchi E, Salati S, Cazzola M, Tagliafico E, Vannucchi AM, Manfredini R; AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) investigators.

Blood Cancer J. 2017 Dec 8;7(12):638. doi: 10.1038/s41408-017-0010-2.

34.

Gene expression and risk of leukemic transformation in myelodysplasia.

Shiozawa Y, Malcovati L, Gallì A, Pellagatti A, Karimi M, Sato-Otsubo A, Sato Y, Suzuki H, Yoshizato T, Yoshida K, Shiraishi Y, Chiba K, Makishima H, Boultwood J, Hellström-Lindberg E, Miyano S, Cazzola M, Ogawa S.

Blood. 2017 Dec 14;130(24):2642-2653. doi: 10.1182/blood-2017-05-783050. Epub 2017 Nov 2.

PMID:
29097382
35.

An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?

Cazzola M, Rogliani P, Puxeddu E, Ora J, Matera MG.

Expert Rev Respir Med. 2018 Jan;12(1):43-54. doi: 10.1080/17476348.2018.1398086. Epub 2017 Nov 3. Review.

PMID:
29082808
36.

Pharmacogenetic and pharmacogenomic considerations of asthma treatment.

Matera MG, Rinaldi B, Calzetta L, Cazzola M.

Expert Opin Drug Metab Toxicol. 2017 Nov;13(11):1159-1167. doi: 10.1080/17425255.2017.1391215. Epub 2017 Oct 23. Review.

PMID:
28992739
37.

Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study.

Shute JK, Calzetta L, Cardaci V, di Toro S, Page CP, Cazzola M.

Pulm Pharmacol Ther. 2018 Feb;48:88-96. doi: 10.1016/j.pupt.2017.10.001. Epub 2017 Oct 3.

PMID:
28986203
38.

Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.

Varettoni M, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L, Gallì A, Porta MGD, Boveri E, Arcaini L, Candido C, Paulli M, Cazzola M.

Haematologica. 2017 Dec;102(12):2077-2085. doi: 10.3324/haematol.2017.172718. Epub 2017 Oct 5.

39.

Acute exacerbations of COPD: risk factors for failure and relapse.

Mantero M, Rogliani P, Di Pasquale M, Polverino E, Crisafulli E, Guerrero M, Gramegna A, Cazzola M, Blasi F.

Int J Chron Obstruct Pulmon Dis. 2017 Sep 8;12:2687-2693. doi: 10.2147/COPD.S145253. eCollection 2017. Review.

40.

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Sep 1;127(9):3557. doi: 10.1172/JCI96202. Epub 2017 Sep 1. No abstract available.

41.

Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease.

Cazzola M, Rogliani P.

J Comp Eff Res. 2017 Oct;6(7):627-636. doi: 10.2217/cer-2017-0037. Epub 2017 Aug 25.

PMID:
28840753
42.

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM.

Blood. 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032. Epub 2017 Aug 21. No abstract available.

43.

In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids.

Cazzola M, Rogliani P.

Evid Based Med. 2017 Oct;22(5):183-184. doi: 10.1136/ebmed-2017-110726. Epub 2017 Aug 11. Review. No abstract available.

PMID:
28801320
44.

Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus.

Cazzola M, Rogliani P, Calzetta L, Lauro D, Page C, Matera MG.

Trends Pharmacol Sci. 2017 Oct;38(10):940-951. doi: 10.1016/j.tips.2017.07.003. Epub 2017 Aug 7. Review.

PMID:
28784329
45.

Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.

Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG.

COPD. 2017 Oct;14(5):552-563. doi: 10.1080/15412555.2017.1347918. Epub 2017 Jul 28.

PMID:
28753070
46.

Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi.

Calzetta L, Rogliani P, Mattei M, Alfonsi P, Cito G, Pistocchini E, Cazzola M, Matera MG.

COPD. 2017 Oct;14(5):526-532. doi: 10.1080/15412555.2017.1344627. Epub 2017 Jul 26.

PMID:
28745522
47.

Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.

Matera MG, Calzetta L, Rinaldi B, Cazzola M.

Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):1007-1013. doi: 10.1080/17425255.2017.1359253. Epub 2017 Jul 24. Review.

PMID:
28737051
48.

Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis.

Calzetta L, Ora J, Cavalli F, Rogliani P, O'Donnell DE, Cazzola M.

Respir Med. 2017 Aug;129:189-198. doi: 10.1016/j.rmed.2017.06.020. Epub 2017 Jun 29. Review.

PMID:
28732830
49.

Adherence to COPD treatment: Myth and reality.

Rogliani P, Ora J, Puxeddu E, Matera MG, Cazzola M.

Respir Med. 2017 Aug;129:117-123. doi: 10.1016/j.rmed.2017.06.007. Epub 2017 Jun 13. Review.

PMID:
28732818
50.

Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi.

Calzetta L, Rogliani P, Facciolo F, Rendina E, Cazzola M, Matera MG.

Eur J Pharmacol. 2017 Oct 5;812:147-154. doi: 10.1016/j.ejphar.2017.07.026. Epub 2017 Jul 14.

PMID:
28716723

Supplemental Content

Loading ...
Support Center